[by Yu, Suin] "The 'Seoul Digital Biocity (S-DBC)' project already contains many of the core components required to establish an ecosystem similar to the 'Boston Bio Cluster,' but the ability to fully support incubators will be realized only when venture capital (VC), infrastructure, and forward-loo
[by Jin, Yu Jeong] Tiumbio announced on November 25 that the World Health Organization (WHO) has approved the International Nonproprietary Name (INN) for its anticancer drug candidate, TU2218 (development code), as ‘Tosposertib.’The name ‘Tosposertib’ combined the term ‘tospo,’ meaning ‘together,’ w
[by Ji, Yong Jun] Neurophet, an AI-based company specializing in the diagnosis and treatment of brain disorders, announced on November 25 that it is conducting a joint research collaboration with the Florey Institute of Neuroscience and Mental Health (hereinafter referred to as Florey) in Australia
[by Ji, Yong Jun] Inventage Lab has continued to advance its partnership with the global pharmaceutical company Boehringer Ingelheim to develop long-acting injectable therapeutics utilizing peptide-based drug candidates. Building upon the initial joint research agreement established in September 202
[by Ji, Yong Jun] Shaperon announced on November 21 that it has secured a patent in Australia for the core composition of its atopic dermatitis treatment candidate, ‘NuGel.’With the issuance of this patent, the company has secured long-term exclusivity for NuGel, extending the patent protection peri
[by Sung, Jae Jun] ToolGen, a gene-editing technology developer, announced on November 24 that it has entered into a strategic cross-licensing agreement with GenEditBio, a Hong Kong-based lipid nanoparticle (LNP) platform company, to co-develop in vivo gene editing therapies.The collaboration forms
[by Yu, Suin] A new era is expected to soon dawn where early detection of stroke-related health abnormalities and timely interventions may be achievable through simple interaction with an artificial intelligence (AI) model on a smartphone.Professor Seo Woo-keun from the Department of Neurology at Sa
[by Kang, In Hyo] Entering clinical trials in new drug development signifies the point at which a candidate is first administered to humans. For this reason, pharmaceutical companies conduct rigorous preclinical evaluations, including extensive animal toxicity and safety testing, to ensure that a dr
[by Lee, Young Sung] The vast stretch of subway depots and driver's license testing grounds becomes strikingly apparent when viewed from the rooftop of the Nowon District Office in Seoul. This landscape, however, is poised for a major transformation. By 2031, the area will be redeveloped into a stat
[by Jin, Yu Jeong] Huons Meditech, a medical device subsidiary of Huons Group, showcased its flagship products, including the ‘Dermashine’ series, at one of the world’s leading medical exhibitions.Huons Meditech announced on the 20th that it took part in ‘MEDICA 2025,’ held in Düsseldorf, Germany, f
[더바이오 이영성 기자] 지하철 차량기지와 운전면허시험장이 끝없이 펼쳐진 자리가 서울 노원구청 옥상에서 내려다보면 더욱 실감이 난다. 이 풍경은 머지않아 완전히 달라질 예정이다. 2031년 이 대지는 최첨단 바이오산업 클러스터로 탈바꿈한다. 바이오 스타트업들이 입주할 공용 연구시설을 시작으로 중견·대형 제약바이오기업들의 사옥, 병원, 대규모 쇼핑몰과 영화관 등 복합문화시설을 품는 ‘바이오 콤플렉스’가 세워진다.서울시와 노원구가 추진 중인 ‘서울 디지털바이오시티(S-DBC)’ 조성이 본격 궤도에 오르고 있다. 노원의 미래를 그리는 이
[by Yu, Suin] Findings from a study evaluating the efficacy of the immunotherapy pembrolizumab in patients with locally advanced thymic epithelial tumors have now been published. Recognized as the first globally meaningful clinical investigation conducted specifically in thymic cancer patients, the
[by Jin, Yu Jeong] Huons Meditech, a medical device subsidiary of Huons Group, announced on the 19th that it held strategic discussions with its Indian partner regarding local assembly production and global business expansion.Huons Meditech recently invited core executives of Vasu Group to Korea to
[by Ji, Yong Jun] Aimed Bio, which has out-licensed its three-product antibody-drug conjugate (ADC) pipeline valued at roughly KRW 3 trillion (approximately USD 2 billion), is now preparing for a KOSDAQ listing. The company has obtained technology license agreements for all three ADC candidates at t
[by Yu, Suin] According to the results of the “Public Perception Survey on Drug Innovation” conducted by the research agency Macromill Embrain, a majority of Koreans believe that the evaluation of “innovation” in new medicines should include not only clinical outcomes but also actual patient access.
[더바이오 강인효 기자] 신약 개발 과정에서 임상에 진입한다는 것은 곧 사람에게 약물을 투여하는 단계에 들어섰다는 의미다. 초기 임상에서 안전성이 가장 먼저 검증돼야 하는 이유도 여기에 있다. 이 때문에 제약사는 임상에 앞서 동물실험 등을 통해 독성과 안전성을 면밀히 확인한다.그러나 동물실험에서 안전성이 확보됐다고 해서 해당 약물이 사람에게서 동일한 효능을 보장하는 것은 아니다. 생물학적 환경 차이로 인해 비임상 단계에서 확인된 약효가 임상에서 재현되지 않는 사례는 흔하다.이 때문에 업계에서는 임상 진입 전 단계에서 ‘인간과 유사한
[by Ji, Yong Jun] Il-yang Pharm announced on November 17 that it presented posters on the pharmacodynamic properties and clinical outcomes of Noltec Plus and Supect at ‘AAPS PharmSci 360,’ hosted by the American Association of Pharmaceutical Scientists (AAPS).AAPS PharmSci 360, held from November 9
[by Ji, Yong Jun] Huons N, a lifecare solutions company under Huons Group, is strengthening its manufacturing capabilities by acquiring a health functional food (HFF) manufacturer Biorosette Co., Ltd.Huons N has announced on November 17 that the company has acquired 250 thousand shares in Biorosette
[by Kang, In Hyo] CTCELLS, a Korean liquid biopsy company, announced on November 14 that it has signed a research service agreement with the multinational pharmaceutical company Daiichi Sankyo to conduct protein expression studies using circulating tumor cells (CTCs).The study will employ CTCELLS' p
[by Lee, Young Sung] On November 16, at the “Korea-U.S. Tariff Negotiation Follow-up Public-Private Joint Meeting” held at the Presidential Office in Yongsan, Celltrion Group Chairman Seo Jung-jin presented the group's mid- to long-term strategy. This included plans for facility investments and expa
